, Volume 22, Issue 4, pp 344–352 | Cite as

Antibody array strategy for human growth factor secretome profiling of GH-secreting adenomas

  • Orly Ozeri
  • Zvi R. Cohen
  • Moshe Hadani
  • Dvora Nass
  • Ilan Shimon
  • Hadara RubinfeldEmail author



To test if the antibody array strategy could be utilized to simultaneously detect the secretion of multiple growth factors by human pituitary GH-adenomas and to measure octreotide-induced alterations.


Specimens of human pituitary adenomas were cultured and incubated with or without octreotide for 24 h. Conditional media were analyzed by human growth factor antibody array and VEGF concentrations were measured by ELISA. Media were also analyzed for GH concentrations. p21 expression levels were examined by Western blot of the specimens lysates.


The antibody arrays successfully identified growth factors secreted by GH-adenomas in vitro. Octreotide treatment induced both elevations and reductions in growth factors secretion. GH response to octreotide was measured, and in this small-sized study resistant and sensitive GH-adenomas presented with no unique secretome pattern of each of the groups. Octreotide-induced VEGF alterations analyzed by the antibody array and by ELISA were not fully matched.


This study suggests that the broad proteomic strategy of antibody arrays may be utilized to study the growth factors secretion pattern of GH-adenomas and its regulation by somatostatin analogs or other compounds.


GH-adenomas Growth factors Secretome VEGF 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Johnson LK, Baxter JD, Vlodavsky I, Gospodarowicz D (1980) Epidermal growth factor and expression of specific genes: effects on cultured rat pituitary cells are dissociable from the mitogenic response. Proc Natl Acad Sci USA 77(1):394–398Google Scholar
  2. 2.
    Schonbrunn A, Krasnoff M, Westendorf JM, Tashjian AH Jr (1980) Epidermal growth factor and thyrotropin-releasing hormone act similarly on a clonal pituitary cell strain. Modulation of hormone production and inhbition of cell proliferation. J Cell Biol 85(3):786–797Google Scholar
  3. 3.
    Yajima Y, Saito T (1984) The effects of epidermal growth factor on cell proliferation and prolactin production by GH3 rat pituitary cells. J Cell Physiol 120(2):249–256. Google Scholar
  4. 4.
    Delidow BC, Billis WM, Agarwal P, White BA (1991) Inhibition of prolactin gene transcription by transforming growth factor-beta in GH3 cells. Mol Endocrinol 5(11):1716–1722. Google Scholar
  5. 5.
    Qian X, Jin L, Grande JP, Lloyd RV (1996) Transforming growth factor-beta and p27 expression in pituitary cells. Endocrinology 137(7):3051–3060. Google Scholar
  6. 6.
    Sarkar DK, Kim KH, Minami S (1992) Transforming growth factor-beta 1 messenger RNA and protein expression in the pituitary gland: its action on prolactin secretion and lactotropic growth. Mol Endocrinol 6(11):1825–1833. Google Scholar
  7. 7.
    Atkin SL, Landolt AM, Jeffreys RV, Diver M, Radcliffe J, White MC (1993) Basic fibroblastic growth factor stimulates prolactin secretion from human anterior pituitary adenomas without affecting adenoma cell proliferation. J Clin Endocrinol Metabol 77(3):831–837Google Scholar
  8. 8.
    Baird A, Mormede P, Ying SY, Wehrenberg WB, Ueno N, Ling N, Guillemin R (1985) A nonmitogenic pituitary function of fibroblast growth factor: regulation of thyrotropin and prolactin secretion. Proc Natl Acad Sci USA 82(16):5545–5549Google Scholar
  9. 9.
    Liu HZ, Luo P, Chen SH, Shang JH (2013) Basic fibroblast growth factor upregulates expression of growth hormone gene through extracellular signal-regulated kinase 1/2 in GH4 cells. Bratislavske lekarske listy 114(7):376–379Google Scholar
  10. 10.
    Mallo F, Wilson E, Whorwood CB, Singh S, Sheppard MC (1995) Basic and acidic fibroblast growth factor increase prolactin mRNA in a dose-dependent and specific manner in GH3 cells. Mol Cell Endocrinol 114(1–2):117–125Google Scholar
  11. 11.
    Mormede P, Baird A (1988) Estrogens, cyclic adenosine 3′,5′-monophosphate, and phorbol esters modulate the prolactin response of GH3 cells to basic fibroblast growth factor. Endocrinology 122(5):2265–2271. Google Scholar
  12. 12.
    Shahmoon S, Rubinfeld H, Wolf I, Cohen ZR, Hadani M, Shimon I, Rubinek T (2014) The aging suppressor klotho: a potential regulator of growth hormone secretion. Am J Physiol Endocrinol Metab 307(3):E326–E334. Google Scholar
  13. 13.
    Zatelli MC, Piccin D, Vignali C, Tagliati F, Ambrosio MR, Bondanelli M, Cimino V, Bianchi A, Schmid HA, Scanarini M, Pontecorvi A, De Marinis L, Maira G, degli Uberti EC (2007) Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Endocr Relat Cancer 14(1):91–102Google Scholar
  14. 14.
    Gagliano T, Filieri C, Minoia M, Buratto M, Tagliati F, Ambrosio MR, Lapparelli M, Zoli M, Frank G, degli Uberti E, Zatelli MC (2013) Cabergoline reduces cell viability in non functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Pituitary 16(1):91–100. Google Scholar
  15. 15.
    Kurosaki M, Saegert W, Abe T, Ludecke DK (2008) Expression of vascular endothelial growth factor in growth hormone-secreting pituitary adenomas: special reference to the octreotide treatment. Neurol Res 30(5):518–522. Google Scholar
  16. 16.
    Villaume K, Blanc M, Gouysse G, Walter T, Couderc C, Nejjari M, Vercherat C, Cordier-Bussat M, Roche C, Scoazec JY (2010) VEGF secretion by neuroendocrine tumor cells is inhibited by octreotide and by inhibitors of the PI3K/AKT/mTOR pathway. Neuroendocrinology 91(3):268–278. Google Scholar
  17. 17.
    Murray RD, Kim K, Ren SG, Chelly M, Umehara Y, Melmed S (2004) Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. J Clin Invest 114(3):349–356. Google Scholar
  18. 18.
    Hayry P, Raisanen A, Ustinov J, Mennander A, Paavonen T (1993) Somatostatin analog lanreotide inhibits myocyte replication and several growth factors in allograft arteriosclerosis. FASEB J 7(11):1055–1060Google Scholar
  19. 19.
    Asa SL, Ezzat S (1998) The cytogenesis and pathogenesis of pituitary adenomas. Endocrine Rev 19(6):798–827. Google Scholar
  20. 20.
    Ezzat S, Melmed S (1990) The role of growth factors in the pituitary. J Endocrinol Invest 13(8):691–698. Google Scholar
  21. 21.
    Missale C, Fiorentini C, Finardi A, Spano P (1999) Growth factors in pituitary tumors. Pituitary 1(3–4):153–158Google Scholar
  22. 22.
    Ray D, Melmed S (1997) Pituitary cytokine and growth factor expression and action. Endocrine Rev 18(2):206–228. Google Scholar
  23. 23.
    Renner U, Paez-Pereda M, Arzt E, Stalla GK (2004) Growth factors and cytokines: function and molecular regulation in pituitary adenomas. Front Hormone Res 32:96–109Google Scholar
  24. 24.
    Renner U, Pagotto U, Arzt E, Stalla GK (1996) Autocrine and paracrine roles of polypeptide growth factors, cytokines and vasogenic substances in normal and tumorous pituitary function and growth: a review. Eur J Endocrinol 135(5):515–532Google Scholar
  25. 25.
    Schwartz J (2000) Intercellular communication in the anterior pituitary. Endocrine Rev 21(5):488–513. Google Scholar
  26. 26.
    Spada A, Lania A (2002) Growth factors and human pituitary adenomas. Mol Cell Endocrinol 197(1–2):63–68Google Scholar
  27. 27.
    Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I, Lombardi G (2001) Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 86(6):2779–2786. Google Scholar
  28. 28.
    Lasry A, Ben-Neriah Y (2015) Senescence-associated inflammatory responses: aging and cancer perspectives. Trends Immunol 36(4):217–228. Google Scholar
  29. 29.
    Chesnokova V, Zonis S, Kovacs K, Ben-Shlomo A, Wawrowsky K, Bannykh S, Melmed S (2008) p21(Cip1) restrains pituitary tumor growth. Proc Natl Acad Sci USA 105(45):17498–17503. Google Scholar
  30. 30.
    Luque RM, Rodriguez-Pacheco F, Tena-Sempere M, Gracia-Navarro F, Malagon MM, Castano JP (2005) Differential contribution of nitric oxide and cGMP to the stimulatory effects of growth hormone-releasing hormone and low-concentration somatostatin on growth hormone release from somatotrophs. J Neuroendocrinol 17(9):577–582. Google Scholar
  31. 31.
    Luque RM, Duran-Prado M, Garcia-Navarro S, Gracia-Navarro F, Kineman RD, Malagon MM, Castano JP (2006) Identification of the somatostatin receptor subtypes (sst) mediating the divergent, stimulatory/inhibitory actions of somatostatin on growth hormone secretion. Endocrinology 147(6):2902–2908. Google Scholar
  32. 32.
    Cordoba-Chacon J, Gahete MD, Culler MD, Castano JP, Kineman RD, Luque RM (2012) Somatostatin dramatically stimulates growth hormone release from primate somatotrophs acting at low doses via somatostatin receptor 5 and cyclic AMP. J Neuroendocrinol 24(3):453–463. Google Scholar
  33. 33.
    Rubinek T, Rubinfeld H, Hadani M, Barkai G, Shimon I (2005) Nitric oxide stimulates growth hormone secretion from human fetal pituitaries and cultured pituitary adenomas. Endocrine 28(2):209–216. Google Scholar
  34. 34.
    Uretsky AD, Weiss BL, Yunker WK, Chang JP (2003) Nitric oxide produced by a novel nitric oxide synthase isoform is necessary for gonadotropin-releasing hormone-induced growth hormone secretion via a cGMP-dependent mechanism. J Neuroendocrinol 15(7):667–676Google Scholar
  35. 35.
    Rodriguez-Pacheco F, Luque RM, Garcia-Navarro S, Gracia-Navarro F, Castano JP, Malagon MM (2005) Ghrelin induces growth hormone (GH) secretion via nitric oxide (NO)/cGMP signaling. Ann N Y Acad Sci 1040:452–453. Google Scholar
  36. 36.
    Bevan JS (2005) Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 90(3):1856–1863. Google Scholar
  37. 37.
    Giustina A, Mazziotti G, Torri V, Spinello M, Floriani I, Melmed S (2012) Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS ONE 7(5):e36411. Google Scholar
  38. 38.
    Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, Vance ML, Rhew D, Kleinberg D, Barkan A (2005) A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 90(7):4405–4410. Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Institute of Endocrinology and Felsenstein Medical Research CenterPetach TikvaIsrael
  2. 2.Rabin Medical CenterPetach TikvaIsrael
  3. 3.Sackler School of MedicineTel AvivIsrael
  4. 4.Tel-Aviv UniversityTel AvivIsrael
  5. 5.Department of PathologySheba Medical CenterTel-HashomerIsrael
  6. 6.Department of NeurosurgerySheba Medical CenterTel-HashomerIsrael

Personalised recommendations